🧾 What This Document Is

This is a Form 8-K filing, which companies use to announce major news to investors. This specific filing contains a press release where Artelo Biosciences announces it has officially fixed its compliance problems with the Nasdaq stock exchange. Think of it as the company turning in its homework and getting a passing grade from the teacher.

🏢 What The Company Does

👉 In simple terms, Artelo Biosciences is a drug development company. They are trying to create new medicines by targeting specific chemical pathways in the body related to lipids (fats). Their focus is on hard-to-treat conditions like cancer-related weight loss, chronic pain, skin diseases, and neurological disorders. They are still in the "clinical-stage," meaning their drugs are being tested in people but are not yet approved or for sale.

🎯 The Core News: Regaining Compliance

Artelo received confirmation from Nasdaq that it has fixed two specific listing rule violations:

1. The "Equity Rule" (5550(b)(1)): This rule requires a minimum level of stockholder equity. Artelo has now met this financial threshold.
2. The "Annual Shareholders Meeting Rule" (5620(a)): This rule requires a company to hold an annual meeting for shareholders. Artelo held its reconvened meeting on January 30, 2026, satisfying this requirement.

👉 Why it matters: Being non-compliant with Nasdaq listing rules is a serious issue that can lead to a company's stock being delisted (removed from the exchange). This announcement removes that immediate threat, which is a positive operational milestone.

🔍 The Fine Print: One-Year Watch

There's a catch. Because of these past issues, Artelo will now be on a "mandatory panel monitor" for one year (from the date of the Nasdaq letter). This is like a probation period. During this time, Nasdaq will closely watch the company to ensure it stays in compliance with all listing rules. Any future missteps could lead to quicker delisting action.

💊 Pipeline Update: What They're Working On

The CEO used the announcement to remind investors about their key drug candidates:

• ART27.13: Being developed for cancer anorexia-cachexia syndrome (severe weight and muscle loss in cancer patients). The company mentions "encouraging" interim data from a Phase 2 study and is in "partnership negotiations" for this drug. It's also being tested for glaucoma in another study.
• ART26.12: A non-opioid drug candidate for neuropathic pain. This is significant because it aims to treat severe pain without the addictive risks of opioids.

🌍 Broader Context & Strategy

This filing isn't just about compliance; it's a signal of the company's current state. The CEO, Gregory D. Gorgas, frames this as "putting a matter behind us" so the team can refocus. Their stated strategy is "disciplined execution" and "capital-efficient development"—corporate speak for trying to advance their drugs without burning through too much cash.

⚖️ Strengths & Risks

👍 Strengths:

• Cleared a major administrative hurdle (Nasdaq compliance).
• Has an active pipeline with drugs targeting large, unmet medical needs (cancer cachexia, neuropathic pain).
• Signals a shift in management focus back to core R&D.

⚠️ Risks:

• One-year probation with Nasdaq means the company must remain flawless in its governance.
• The company is clinical-stage with no approved products, meaning it is not yet generating revenue from sales and relies on funding.
• The success of its entire strategy depends on the expensive and risky process of clinical trials.

🧠 The Analogy

It's like a student who was failing a class and on the verge of being expelled. They turned in missing assignments (the shareholder meeting) and proved they had the minimum passing grade (the equity rule). The school lets them stay but puts them on strict academic probation for a year, watching their every move. The student is now saying, "Great, now I can finally focus on my actual studies (the drug pipeline) again."

🧩 Final Takeaway

Artelo Biosciences has fixed its immediate administrative problem with Nasdaq, allowing it to avoid delisting. With that crisis averted, the company is directing attention back to its core mission: advancing its experimental drugs through clinical trials. The key for investors now is watching the progress of ART27.13 and ART26.12, as the company's long-term value hinges entirely on their success.

Investor Relations Contact: Crescendo Communications, LLC, Tel: 212-671-1020, Email: [Not provided in text]